Research ExplorerPublicationsNo effect of the hemoglobin solution HBOC-201 on the respons...

No effect of the hemoglobin solution HBOC-201 on the response of the rat R1H tumor to fractionated irradiation

Standard

No effect of the hemoglobin solution HBOC-201 on the response of the rat R1H tumor to fractionated irradiation. / Raabe, Annette; Gottschalk, André; Hommel, Matthias; Dubben, Hans-Hermann; Strandl, Thomas.

In: STRAHLENTHER ONKOL, Vol. 181, No. 11, 01.11.2005, p. 730-7.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Raabe, A, Gottschalk, A, Hommel, M, Dubben, H-H & Strandl, T 2005, 'No effect of the hemoglobin solution HBOC-201 on the response of the rat R1H tumor to fractionated irradiation', STRAHLENTHER ONKOL, vol. 181, no. 11, pp. 730-7. https://doi.org/10.1007/s00066-005-1418-3

APA

Raabe, A., Gottschalk, A., Hommel, M., Dubben, H-H., & Strandl, T. (2005). No effect of the hemoglobin solution HBOC-201 on the response of the rat R1H tumor to fractionated irradiation. STRAHLENTHER ONKOL, 181(11), 730-7. https://doi.org/10.1007/s00066-005-1418-3

Vancouver

Raabe A, Gottschalk A, Hommel M, Dubben H-H, Strandl T. No effect of the hemoglobin solution HBOC-201 on the response of the rat R1H tumor to fractionated irradiation. STRAHLENTHER ONKOL. 2005 Nov 1;181(11):730-7. https://doi.org/10.1007/s00066-005-1418-3

Bibtex

@article{c935098b9271482da945467af2b3c8c6,
title = "No effect of the hemoglobin solution HBOC-201 on the response of the rat R1H tumor to fractionated irradiation",
abstract = "BACKGROUND AND PURPOSE: Tumor hypoxia is regarded as one important underlying feature of radioresistance. The authors report on an experimental approach to improve tumor response to radiation by combining fractionated irradiation with HBOC-201, an ultrapurified polymerized hemoglobin solution, which is currently used in clinical phase II/III trials as alternative oxygen carrier and proved to be highly effective in tissue oxygenation (tpO(2)).MATERIAL AND METHODS: Subcutaneously growing rhabdomyosarcoma R1H tumors of the rat were treated with either 40 Gy (2 Gy/fraction, 20 fractions in 2 weeks, ambient) followed by graded top-up doses (clamped) alone, or in combination with HBOC-201, or with HBOC-201 plus carbogen (95% O(2) + 5% CO(2)). Local tumor control (TCD50%) and growth delay were used as endpoints. In addition, the effect of HBOC-201 alone or in combination with carbogen on the tpO(2) of tumor and muscle was determined using a flexible stationary probe (Licox, GMS).RESULTS: TCD50% values of 119 Gy (95% confidence interval 103;135), 111 Gy (84;138), and 102 Gy (83;120) were determined for tumors irradiated alone, in combination with HBOC-201, and with HBOC-201 plus carbogen, respectively. Although the dose-response curves showed a slight shift to lower doses when HBOC-201 or HBOC-201 plus carbogen was added, the differences in TCD50% were not statistically significant. No effect was seen on the growth delay of recurrent tumors. HBOC-201 alone did not effect tumor or muscle tpO(2). In combination with carbogen the mean tpO(2) of muscle raised from 23.9 mmHg to 59.3 mmHg (p < 0.05), but this effect was less pronounced than the increase in tpO(2) by carbogen alone.CONCLUSION: Low-dose application of HBOC-201 does not improve the response of the rhabdomyosarcoma R1H of the rat to fractionated irradiation.",
keywords = "Animals, Blood Substitutes, Cell Division, Dose Fractionation, Hemoglobins, Oxygen Consumption, Oxyhemoglobins, Rats, Rhabdomyosarcoma",
author = "Annette Raabe and Andr{\'e} Gottschalk and Matthias Hommel and Hans-Hermann Dubben and Thomas Strandl",
year = "2005",
month = nov,
day = "1",
doi = "10.1007/s00066-005-1418-3",
language = "English",
volume = "181",
pages = "730--7",
journal = "STRAHLENTHER ONKOL",
issn = "0179-7158",
publisher = "Urban und Vogel",
number = "11",

}

RIS

TY - JOUR

T1 - No effect of the hemoglobin solution HBOC-201 on the response of the rat R1H tumor to fractionated irradiation

AU - Raabe, Annette

AU - Gottschalk, André

AU - Hommel, Matthias

AU - Dubben, Hans-Hermann

AU - Strandl, Thomas

PY - 2005/11/1

Y1 - 2005/11/1

N2 - BACKGROUND AND PURPOSE: Tumor hypoxia is regarded as one important underlying feature of radioresistance. The authors report on an experimental approach to improve tumor response to radiation by combining fractionated irradiation with HBOC-201, an ultrapurified polymerized hemoglobin solution, which is currently used in clinical phase II/III trials as alternative oxygen carrier and proved to be highly effective in tissue oxygenation (tpO(2)).MATERIAL AND METHODS: Subcutaneously growing rhabdomyosarcoma R1H tumors of the rat were treated with either 40 Gy (2 Gy/fraction, 20 fractions in 2 weeks, ambient) followed by graded top-up doses (clamped) alone, or in combination with HBOC-201, or with HBOC-201 plus carbogen (95% O(2) + 5% CO(2)). Local tumor control (TCD50%) and growth delay were used as endpoints. In addition, the effect of HBOC-201 alone or in combination with carbogen on the tpO(2) of tumor and muscle was determined using a flexible stationary probe (Licox, GMS).RESULTS: TCD50% values of 119 Gy (95% confidence interval 103;135), 111 Gy (84;138), and 102 Gy (83;120) were determined for tumors irradiated alone, in combination with HBOC-201, and with HBOC-201 plus carbogen, respectively. Although the dose-response curves showed a slight shift to lower doses when HBOC-201 or HBOC-201 plus carbogen was added, the differences in TCD50% were not statistically significant. No effect was seen on the growth delay of recurrent tumors. HBOC-201 alone did not effect tumor or muscle tpO(2). In combination with carbogen the mean tpO(2) of muscle raised from 23.9 mmHg to 59.3 mmHg (p < 0.05), but this effect was less pronounced than the increase in tpO(2) by carbogen alone.CONCLUSION: Low-dose application of HBOC-201 does not improve the response of the rhabdomyosarcoma R1H of the rat to fractionated irradiation.

AB - BACKGROUND AND PURPOSE: Tumor hypoxia is regarded as one important underlying feature of radioresistance. The authors report on an experimental approach to improve tumor response to radiation by combining fractionated irradiation with HBOC-201, an ultrapurified polymerized hemoglobin solution, which is currently used in clinical phase II/III trials as alternative oxygen carrier and proved to be highly effective in tissue oxygenation (tpO(2)).MATERIAL AND METHODS: Subcutaneously growing rhabdomyosarcoma R1H tumors of the rat were treated with either 40 Gy (2 Gy/fraction, 20 fractions in 2 weeks, ambient) followed by graded top-up doses (clamped) alone, or in combination with HBOC-201, or with HBOC-201 plus carbogen (95% O(2) + 5% CO(2)). Local tumor control (TCD50%) and growth delay were used as endpoints. In addition, the effect of HBOC-201 alone or in combination with carbogen on the tpO(2) of tumor and muscle was determined using a flexible stationary probe (Licox, GMS).RESULTS: TCD50% values of 119 Gy (95% confidence interval 103;135), 111 Gy (84;138), and 102 Gy (83;120) were determined for tumors irradiated alone, in combination with HBOC-201, and with HBOC-201 plus carbogen, respectively. Although the dose-response curves showed a slight shift to lower doses when HBOC-201 or HBOC-201 plus carbogen was added, the differences in TCD50% were not statistically significant. No effect was seen on the growth delay of recurrent tumors. HBOC-201 alone did not effect tumor or muscle tpO(2). In combination with carbogen the mean tpO(2) of muscle raised from 23.9 mmHg to 59.3 mmHg (p < 0.05), but this effect was less pronounced than the increase in tpO(2) by carbogen alone.CONCLUSION: Low-dose application of HBOC-201 does not improve the response of the rhabdomyosarcoma R1H of the rat to fractionated irradiation.

KW - Animals

KW - Blood Substitutes

KW - Cell Division

KW - Dose Fractionation

KW - Hemoglobins

KW - Oxygen Consumption

KW - Oxyhemoglobins

KW - Rats

KW - Rhabdomyosarcoma

U2 - 10.1007/s00066-005-1418-3

DO - 10.1007/s00066-005-1418-3

M3 - SCORING: Journal article

C2 - 16254709

VL - 181

SP - 730

EP - 737

JO - STRAHLENTHER ONKOL

JF - STRAHLENTHER ONKOL

SN - 0179-7158

IS - 11

ER -